Former chief medical officer of MyoKardia to lead clinical development at Renovacor PHILADELPHIA and BOSTON, June 02, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS”) diseases resulting from BAG3 gene variants, today announced the appointment […]
Other News
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2021 it granted stock options to purchase an aggregate of 49,500 shares of common stock to eight new employees whose employment commenced in May 2021 as a material inducement to […]
Liquidia Announces FDA Acceptance of New Drug Application Resubmission for LIQ861 (treprostinil) Inhalation Powder
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH). The FDA confirmed that the resubmission was a complete, […]
Data Published in “JACC Heart Failure”Show Benefit of Carillon Device to Patients Suffering from Functional Mitral Regurgitation & Severe Left Ventricular
On behalf of Cardiac Dimensions, please find key outcomes of the analysis “Percutaneous Mitral-Valve Annuloplasty Versus Optimal Medical Therapy in Patients with Secondary Mitral-Regurgitation and Severe Left-Ventricular Enlargement” published in this month’s JACC: Heart Failure. The manuscript can be viewed here: https://cardiacdimensions.com/wp-content/uploads/docs/Anker-Complete-Publication_May-2021.pdf Key outcomes of the analysis are as follows — in the Carillon […]
iRhythm® Technologies Announces Leadership Transition
President and CEO Michael Coyle Steps Down Due to Personal Matters Douglas Devine to Serve as Interim CEO While Search for Permanent CEO is Conducted SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac […]
HD Medical Appoints Shaun Setty, MD as Chief Medical Officer
SANTA CLARA, Calif.–(BUSINESS WIRE)–HD Medical, Inc., the leader in cardiovascular disease (CVD) detection, today announces it has appointed Shaun Setty, MD, as its Chief Medical Officer (CMO). Dr. Setty is a cardiothoracic surgeon in Los Angeles, CA, with over 13 years of experience in pediatric and adult congenital cardiac surgery. […]
LivaNova completes the initial sale of the heart valve business to Gyrus Capital
Further local deals are expected to take place in the course of the year LONDON, United Kingdom – ( BUSINESS WIRE ) – LivaNova PLC (NASDAQ: LIVN), a leader in medical technology and innovation, announced today that it has completed the initial completion of the divestment of its heart valve business (HV) to Gyrus […]
Severe Heart Failure Treatment: FineHeart Successfully Raises €15 million Series B funding With Industrial and Independent Investors
The First In Human implantation of the ICOMS FLOWMAKER® is assured following this financing BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the […]
Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters
ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the full line of OrbusNeich® JADE® percutaneous transluminal angioplasty (PTA) over-the-wire (OTW) balloon catheters is now available in the U.S. CSI […]
Occlutech takes important step towards approval in China
SCHAFFHAUSEN, Switzerland, June 1, 2021 /PRNewswire/ — Occlutech AG (“Occlutech” or the “Company”) today announces that the planned recruitment of 180 patients has been reached in the Company’s trial in China for its ASD Occluder. The Occlutech ASD Occluder is used in the treatment of Atrial Septal Defects (ASD), which is a congenital heart condition. The […]



